NDAORALCAPSULEPriority Review
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority ReviewIRA Negotiated
IMBRUVICA (ibrutinib) by AbbVie is protein kinase inhibitors [moa]. Approved for chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma and 1 more indications. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMBRUVICA (ibrutinib) is an oral kinase inhibitor that works as a Bruton's tyrosine kinase (BTK) inhibitor, approved by the FDA on November 13, 2013. The drug is indicated for various hematologic malignancies and is administered as an oral capsule. It represents a foundational therapy in the kinase inhibitor class and remains a standard-of-care option in its therapeutic area.
$2.4BPart D
9.0 years to LOEMechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Worked on IMBRUVICA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.